FDA to Review Blue Earth Diagnostics' Emerging PSMA/PET Agent for Prostate Cancer

One prospective multicenter study found the radiohybrid prostate-specific membrane antigen (PSMA) agent 18F-rhPSMA-7.3 had an 83 percent detection rate in nearly 400 men with suspected prostate cancer.

Image IQ Quiz: 56-Year-Old Man with Weight Loss and Gradual Abdominal Distention

What is the diagnosis?

Diagnostic Imaging's Advances in AI: September 2022

Catch up on the top AI-related radiology content of the past month.